Endocrine Abstracts

Objective: Osteoporosis and vertebral fractures (VFs) are frequently observed in HIV-infected men. Whereas bisphosphonates seem effective on bone mineral density (BMD) maintenance in HIV-men, data on VFs are lacking. We aimed to evaluate the long-term efficacy of bisphosphonates on VFs in HIV-infected men.Design: Real-life longitudinal retrospective study on 118 consecutive HIV-infected males (median age at inclusion 53 years). Median time between first ...

Acromegaly is associated with skeletal fragility and high risk of vertebral fractures (VFs), but the determinants of such a risk are still under investigation and it is not clear whether replacement therapies of coexistent hypopituitarism may influence prevalence and incidence of VFs. In this cross sectional study, fourty acromegaly patients (24 M, 16 F; median age, 57 years; range, 25–72), 20 with active disease, were evaluated for the effects of replacement therapy of c...

With HAART (Highly Active Anti-Retroviral Therapy) introduction, HIV infection history has radically changed. Increased survival has led to new complications, including osteoporosis. The pathogenesis of osteoporosis in HIV patients is multifactorial: virus, HAART, smoking, alcohol, physical inactivity, comorbidities, and hypogonadism can interact in bone depletion.Aim of this study was to evaluate the prevalence of osteoporosis, vertebral fractures (VF) ...

GH deficiency (GHD) and excess of glucocorticoids are associated with increased risk of fragility fractures. Most adult GHD patients have other pituitary deficiencies, but it is unclear whether these deficiencies or their overreplacement therapies may influence the bone disease occurring in GHD. The aim of this study was to evaluate whether the prevalence of vertebral fractures may be influenced by glucocorticoid replacement therapy in hypopituitary males with GHD. We studied ...

Clinical trials have demonstrated that pegvisomant therapy is highly efficacious, normalizing serum IGF-I levels in the majority of patients with acromegaly. Multiple factors could influence the dose of pegvisomant required to normalize IGF-I, that ranging from 10 to 40 mg/day. However, the determinants of this variability are unknown and, to date, there is no specific recommendation to adjust the dose to the type of patient. Lack of exon 3 of the Growth Hormone receptor (d3-G...

Osteopathy is an emerging complication of acromegaly, characterized by increased bone turnover, profound abnormalities in trabecular bone structure and high risk of vertebral fractures (VFs). The therapeutic management of skeletal fragility in acromegaly is a challenge, since the risk of fractures may remain high after the control of acromegaly and the effectiveness of bone-active drugs in this clinical setting is unknown. In this retrospective-multicenter study, we aimed at e...